Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. is a biopharmaceutical company based in Cranford, New Jersey, focused on developing and commercializing first-in-class critical care products, with an emphasis on oncology, anti-infectives in adjunct cancer care, and unique prescription products. The company's strategy involves targeting unmet medical needs with therapeutic products that have lower development risk, often through new formulations of previously approved drugs with existing safety and efficacy data. Citius Pharmaceuticals aims to achieve leading market positions by focusing on products with intellectual property and regulatory exclusivity protection that offer competitive advantages ¹.

The company's core business model revolves around the development and commercialization of proprietary product candidates. As of December 2025, Citius Pharmaceuticals became a commercial company with the launch of LYMPHIR by its majority-owned subsidiary, Citius Oncology ². The company generates revenue through product sales and seeks to monetize its pipeline through strategic partnerships, joint ventures, mergers, acquisitions, or licensing transactions ³. The primary customer segments are highly influenced by key opinion leaders and involve a relatively small number of prescribing physicians, allowing for a manageable commercialization effort ⁴.

One of Citius Pharmaceuticals' key product candidates is LYMPHIR (denileukin diftitox), an engineered IL-2 diphtheria toxin fusion protein, approved by the FDA in August 2024 for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL) ⁵. LYMPHIR was launched in December 2025 by Citius Oncology, a majority-owned subsidiary in which Citius Pharma holds approximately 77.9% of outstanding common stock as of December 17, 2025 ⁶. The company estimates the addressable U.S. market for LYMPHIR to exceed $400 million ⁷. LYMPHIR's mechanism of action involves killing tumors by binding to IL-2 receptors and depleting immunosuppressive regulatory T lymphocytes (Tregs) ⁸. Preliminary results from a Phase 1 trial combining LYMPHIR with pembrolizumab in recurrent solid tumors showed an overall response rate (ORR) of 27% (4/15) and a clinical benefit rate of 33% (5/15) among evaluable patients, with a median progression-free survival (PFS) of 57 weeks for those achieving clinical benefit ⁹.

Another late-stage product candidate is Mino-Lok, a patented antibiotic lock solution designed to treat and salvage infected central venous catheters (CVCs) in patients with catheter-related bloodstream infections (CRBSIs) ¹⁰. Mino-Lok works by breaking down biofilm barriers, eradicating bacteria, and providing anti-clotting properties ¹¹. A Phase 2b study demonstrated 100% efficacy in salvaging CVCs, comparable to removal and replacement, with no significant adverse events (SAEs) compared to an 18% SAE rate in the control group ¹². The Phase 3 trial, which enrolled 241 patients across 34 sites in the U.S. and India, met its primary endpoint with a statistically significant improvement in time to catheter failure for Mino-Lok compared to standard-of-care antibiotic lock solution ¹³. The median time to catheter failure in the Mino-Lok arm was significantly prolonged (p ≤ 0.0006), catheter retention was achieved in 57% of Mino-Lok patients versus 38% in the control arm (p = 0.0025), and rates of clinical and microbiological failure were significantly lower in the Mino-Lok arm (p = 0.0058 and p = 0.012, respectively) ¹⁴. The company estimates the potential U.S. market for Mino-Lok to be approximately $500 million to $1 billion ¹⁵.

Halo-Lido is a topical formulation of halobetasol propionate and lidocaine intended for the treatment of hemorrhoids ¹⁶. There are currently no FDA-approved prescription drug products for hemorrhoids, and existing topical prescription products are available due to the DESI program without FDA-reviewed efficacy or safety data ¹⁷. A Phase 2b study of Halo-Lido showed that 42% of patients in the high-dose group reached a Meaningful Change Threshold (MCT) in hemorrhoidal symptoms, compared to 29% for high-dose halobetasol alone and 21% for lidocaine alone, with a statistically significant improvement over lidocaine alone (CMH test, p = 0.035) ¹⁸. The company believes Halo-Lido represents an attractive, low-risk product opportunity with meaningful upside potential and intends to monetize its value by seeking a strategic or financial partner ¹⁹.

NoveCite, a majority-owned subsidiary in which Citius Pharma owns 75% of the outstanding capital stock, is focused on developing mesenchymal stem cell therapy (NC-iMSCs) for acute respiratory conditions, with a near-term focus on Acute Respiratory Distress Syndrome (ARDS) ²⁰. NC-iMSCs are described as differentiated and superior to donor-derived MSCs, offering higher potency, unlimited supply, consistent quality, and significantly higher expansion capability ²¹. Preliminary data from a proof-of-concept large animal study showed improvement in critical parameters such as oxygenation, systemic shock, and reduced lung injury ²². The global market for ARDS is 3 million cases annually, with approximately 200,000 cases in the U.S., and there are no approved treatments for ARDS ²³. The company has paused most development initiatives for NoveCite to prioritize LYMPHIR and its other product candidates ²⁴.

For the fiscal year ended September 30, 2025, Citius Pharmaceuticals reported no revenues ²⁵. The company incurred a net loss of $39,740,269 ²⁶, compared to a net loss of $39,425,839 in the prior year ²⁷. Operating expenses totaled $38,525,608 ²⁸. Research and development expenses were $9,156,474 ²⁹, general and administrative expenses were $18,532,843 ³⁰, and stock-based compensation was $10,836,291 ³¹. The company had an operating loss of $38,525,608 ³². Interest income was $110,081 ³³, and interest expense was $267,782 ³⁴. Income tax expense was $1,056,960 ³⁵. Net cash used in operating activities was $26,552,738 ³⁶. As of September 30, 2025, cash and cash equivalents were $4,252,290 ³⁷, total current liabilities were $44,914,740 ³⁸, and the accumulated deficit was $238,804,129 ³⁹.

Year-over-year, the net loss increased by $314,430 ⁴⁰. Research and development expenses decreased by $2,750,127 ⁴¹, primarily due to decreased costs for Mino-Lok following the completion of its Phase 3 trial ⁴² and lower costs for Halo-Lido after its Phase 2 study completion ⁴³. R&D costs for LYMPHIR, however, increased by $3,209,611 ⁴⁴ due to expenses for a drug substance batch needed for pre-license inspection ⁴⁵. General and administrative expenses increased by $283,441 ⁴⁶, mainly due to higher costs for pre-launch commercial activities for LYMPHIR ⁴⁷. Stock-based compensation expense decreased by $1,003,387 ⁴⁸. Interest income decreased from $758,000 in 2024 to $110,081 in 2025 ⁴⁹.

During the reported period, Citius Oncology launched LYMPHIR in December 2025 following its FDA approval in August 2024 ⁵⁰. The company completed patient enrollment for the Mino-Lok Phase 3 trial in late December 2023 and announced positive topline results in May 2024 ⁵¹. In November 2024, a Type C meeting with the FDA provided a pathway for a future New Drug Application (NDA) submission for Mino-Lok ⁵². For Halo-Lido, positive results from the Phase 2b study were announced in June 2023, and a Phase 2 meeting with the FDA was held in April 2024 to discuss the go-forward path ⁵³. Citius Pharma also executed a 1-for-25 reverse stock split effective November 25, 2024 ⁵⁴.

Citius Pharmaceuticals expects to incur additional expenses in the future as it continues to develop its product candidates, including seeking regulatory approval and protecting its intellectual property ⁵⁵. The company anticipates that research and development expenses will continue to decrease in fiscal 2026 as it focuses on the commercialization of LYMPHIR and has completed the Phase 3 trial for Mino-Lok ⁵⁶.

A major growth area for the company is the commercialization of LYMPHIR, which launched in December 2025 ⁵⁷. Citius Oncology, the majority-owned subsidiary responsible for LYMPHIR, has established initial sales and marketing capabilities by contracting with a large third-party commercial sales and marketing organization ⁵⁸. This includes a dedicated field force and marketing programs tailored for physicians and patients ⁵⁹. Distribution agreements have been finalized with Cardinal Health, Cencora, and McKesson Corporation ⁶⁰. Additionally, Citius Oncology has partnered with EVERSANA for integrated pre- and post-launch services, including medical information, pharmacovigilance, revenue cycle management, and data analytics ⁶¹. LYMPHIR's inclusion in the National Comprehensive Cancer Network (NCCN) guidelines with a Category 2A recommendation in September 2024 is expected to assist in obtaining coverage and reimbursement from the Centers for Medicare and Medicaid Services (CMS) ⁶². In February 2025, LYMPHIR was assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code (J9161) by CMS, which is a key step in facilitating reimbursement and patient access ⁶³. Citius Oncology is also engaging with regional distribution partners for Named Patient Programs (NPPs) in Europe, South America, and the Middle East, having entered an exclusive distribution agreement with Integris Pharma S.A. covering Greece, Cyprus, Malta, Bulgaria, Romania, Croatia, Serbia, Albania, Bosnia Herzegovina, Kosovo, Montenegro, and North Macedonia ⁶⁴.

For Mino-Lok, the company held a Type C meeting with the FDA in November 2024, which provided clear, constructive, and actionable guidance for a future New Drug Application (NDA) submission ⁶⁵. The company continues to engage with the FDA to define the regulatory path forward ⁶⁶. Mino-Lok has received Qualified Infectious Disease Product (QIDP) designation, which provides an additional five years of market exclusivity, potentially combining with three years of exclusivity for new strength and formulation to result in a total of eight years of market exclusivity, regardless of patent protection ⁶⁷. The company believes there is no FDA-approved alternative currently available to salvage infected indwelling central venous catheters ⁶⁸.

Regarding Halo-Lido, Citius Pharma had a Phase 2 meeting with the FDA in April 2024 to discuss the go-forward path for the program, and ongoing engagement with the FDA is planned for the next steps of development ⁶⁹. The company is actively pursuing intellectual property protections for its proprietary Patient Reported Outcome (PRO) instrument, Hemorrhoid Quality of Life Index (HQLI), and has filed patent applications on its CITI-002 formulations ⁷⁰. If approved, Halo-Lido would be the only prescription product for hemorrhoids with proven safety and efficacy data, potentially qualifying for three years of market exclusivity for its dosage strength and formulation ⁷¹.

The company expects to finance its operations through a combination of equity offerings, debt financings, collaborations, or other strategic transactions ⁷². As of September 30, 2025, the company had outstanding milestone payment obligations of $2,900,000 to Eisai and $19,750,000 to Dr. Reddy's ⁷³. Additionally, there are minimum purchase commitments under manufacturing and supply agreements totaling approximately $16.2 million for drug substance (with $8.5 million for calendar year 2025, $5.3 million for 2026, and $2.4 million for 2026 pass-throughs and consumable components) ⁷⁴, and approximately $4.9 million for finished drug product completion and packaging ($1.2 million in 2025, $1.9 million in 2026, and $1.8 million in 2027) ⁷⁵. The company expects to have sufficient funds to continue operations through March 2026, after accounting for a $6.0 million capital raise in October 2025 and an $18.0 million capital raise by Citius Oncology in December 2025 ⁷⁶. Additional capital will be needed to support operations beyond March 2026 ⁷⁷.

Citius Pharmaceuticals faces substantial risks, including an explanatory paragraph in its independent registered public accounting firm's report stating substantial doubt about its ability to continue as a going concern, with estimated sufficient capital only through March 2026 ⁷⁸. The company requires substantial additional funding to support operations, commercialize LYMPHIR, and continue developing other product candidates, which may not be available on acceptable terms or at all ⁷⁹. There is a history of net losses, with $39,740,269 ⁸⁰ and $39,425,839 ⁸¹ for the years ended September 30, 2025 and 2024, respectively, and an accumulated deficit of $238,804,129 ⁸² as of September 30, 2025. The company has outstanding liabilities of $38.4 million and commitments of $22.7 million to third parties for LYMPHIR licensing, supply, and other costs, which if unpaid, could interrupt commercialization or lead to loss of licensing rights ⁸³. The ongoing exploration of strategic alternatives may not result in completed transactions, and failure to secure additional financing or strategic partners could force delays, reductions, or termination of commercialization efforts and business operations ⁸⁴. Both Citius Pharma and Citius Oncology are heavily dependent on the launch and commercial success of LYMPHIR, which has an unproven business strategy and limited operating history ⁸⁵. The company relies exclusively on third parties for formulation and manufacturing, and failure to meet contractual obligations, including timely payments, could result in loss of necessary third-party support ⁸⁶. The markets are highly competitive, with many larger, well-financed companies, and new entrants or established companies may develop more effective or less costly products ⁸⁷. Regulatory approval processes are complex, unpredictable, and costly, with no assurance of timely approval or market acceptance for product candidates ⁸⁸. Even with Fast Track designation for Mino-Lok, a faster development or approval process is not guaranteed ⁸⁹. Healthcare reform measures, including price controls and reimbursement restrictions, could hinder commercial success and reduce revenues ⁹⁰. The company does not own Citius Oncology or NoveCite outright, meaning benefits from commercialization and development will be shared with other stockholders, and future equity issuances could further dilute ownership ⁹¹. The NoveCite product candidate, based on novel iPSC-derived cell technologies, faces uncertainties in regulatory approval, development time, cost, and ability to successfully initiate and complete clinical development ⁹².

Management's overall tone emphasizes the company's transition to a commercial entity with the launch of LYMPHIR in December 2025, while continuing to advance its late-stage pipeline. They highlight the strategic focus on first-in-class critical care products with lower development risk, often through new formulations of previously approved drugs. Management explicitly states that the company expects to have sufficient funds to continue operations through March 2026 ⁹³, after taking into account a $6.0 million capital raise in October 2025 ⁹⁴ and an $18.0 million capital raise by Citius Oncology in December 2025 ⁹⁵. However, they acknowledge the need to raise additional capital to support operations beyond March 2026 ⁹⁶. Key strategic priorities include the successful commercialization of LYMPHIR, advancing the regulatory path for Mino-Lok towards an NDA submission, and exploring strategic or financial partnerships for Halo-Lido. Management also notes the pausing of most development initiatives for NoveCite to prioritize LYMPHIR and other product candidates ⁹⁷.